As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback